Literature DB >> 6980023

Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency.

H A Simmonds, D R Webster, D Perrett, S Reiter, R J Levinsky.   

Abstract

dATP, dADP, and dAMP equalled or exceeded the depleted levels of ATP, ADP, and AMP in erythrocytes from two children with adenosine deaminase (ADA; EC 3.5.4.4) deficiency. dATP and dADP were identified in the mononuclear cells of only one child. The levels of deoxyadenosine compounds fell dramatically after enzyme replacement therapy and were no longer detectable in the urine or in mononuclear cells. Erythrocyte adenosine nucleotide levels showed a corresponding increase. Intact erythrocytes prior to treatment contained adenine, presumed to be from deoxyadenosine degraded during extraction. Adenosine at high concentrations in vitro increased both dATP and ATP levels and decreased intracellular deoxyadenosine levels. There was no significant deamination of either [8-14C]adenosine or deoxyadenosine by intact ADA-deficient erythrocytes. About 90% of adenosine was metabolized to ATP at substrate concentrations from 10-100 microM, compared to 40-60% of deoxyadenosine metabolized to dATP. These studies suggest that (i) high intracellular deoxyadenosine levels may be necessary in vivo to sustain the raised dATP levels in ADA deficiency. (ii) When ADA is inhibited or absent, deoxyadenosine is removed rapidly from the circulation by the human erythrocyte utilizing an adenosine transport system linked to both ADA and adenosine kinase (EC 2.7.1.20).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980023     DOI: 10.1007/BF01115116

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  6 in total

Review 1.  Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist.

Authors:  Rakesh Kumar Pilania; Aaqib Zaffar Banday; Saniya Sharma; Rajni Kumrah; Vibhu Joshi; Sathish Loganathan; Manpreet Dhaliwal; Ankur Kumar Jindal; Pandiarajan Vignesh; Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

2.  Prenatal diagnosis of three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of gestation in fetuses with adenosine deaminase deficiency.

Authors:  D C Linch; R J Levinsky; C H Rodeck; K A Maclennan; H A Simmonds
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

3.  Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  G Morgan; R J Levinsky; K Hugh-Jones; L D Fairbanks; G S Morris; H A Simmonds
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

4.  Substrate inhibition of adenosine phosphorylation in adenosine deaminase deficiency and adenosine-mediated inhibition of PP-ribose-P dependent nucleotide synthesis in hypoxanthine phosphoribosyltransferase deficient erythrocytes.

Authors:  F F Snyder; C Dyer; J E Seegmiller; R M Goldblum; G C Mills; F C Schmalstieg
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 5.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.

Authors:  Isabelle Meyts; Ivona Aksentijevich
Journal:  J Clin Immunol       Date:  2018-06-27       Impact factor: 8.317

6.  Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure.

Authors:  Gianluca Dell'Orso; Alice Grossi; Federica Penco; Roberta Caorsi; Elena Palmisani; Paola Terranova; Francesca Schena; Michela Lupia; Erica Ricci; Shana Montalto; Filomena Pierri; Isabella Ceccherini; Francesca Fioredda; Carlo Dufour; Marco Gattorno; Maurizio Miano
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.